Prostate cancer breakthrough drug 'to be available next year'
You are here: KAMAGRA TABLETS | KAMAGRA ORAL JELLY | DIAZEPAM VALIUM UK NEXT DAY » News » Prostate cancer breakthrough drug 'to be available next year'
May-04-2010 Abiraterone hit the headlines two years ago, with stunning trial results in which it shrank tumours in 80 per cent of men whose cancer had spread throughout their body.
The once-a-day drug also eased pain in many and was hailed as the biggest
breakthrough in the field for 60 year.
Now further tests have underlined its potential and larger trials are under
way. If they are successful, it could be prescribed to men in the advanced
stages of the disease as early as next year, giving them the hope of precious
extra months with their families.
Abiraterone is a 'home-grown' drug, discovered by scientists funded by Cancer
Research UK and working at the Institute for Cancer Research at London's Royal
Marsden Hospital.
It works by blocking testosterone, including any made by the tumour itself,
from fuelling the cancer's growth.
In the latest study, it was given in pill form to 47 men in advanced stages
of the cancer who had exhausted all other treatment options, including a drug
called docetaxel.
Researcher Johann de Bono said: 'Docetaxel is an important drug but it
extends life for an average of just two to three months, so there is a desperate
need to improve options for late-stage patients. Abiraterone shrank or
stabilised tumours for an average of almost six months, which is a very
impressive result.'
Levels of PSA, a blood protein used as a measure of tumour growth and spread,
fell in 75 per cent of the men, the Journal of Clinical Oncology reports. Any
sideeffects were mild and easily treated.
Dr Helen Rippon of the Prostate Cancer Charity, which is also funding
research into the drug, said: 'These findings are particularly important as they
offer new hope to men who can quickly run out of treatment options once their
tumour stops responding.'
Prostate is Britain's most common cancer among men and the second highest
killer, after lung cancer. Some 35,000 people a year are diagnosed with it - and
12,000 die.
There are two types, aggressive and non-aggressive.
Two-thirds of victims have the non-aggressive variety and can often lead a
healthy life.
But those with the aggressive version usually die within 18 months of
diagnosis. Abiraterone can shrink aggressive tumours, although the effect does
not last indefinitely.
List By Manufacturer
